|
|
|
| Effect of bevacizumab combined with docetaxel and gemcitabine for treating patients with recurrent platinum-resistant advanced ovarian cancer and the prognosis of the patients within 1 year follow up |
| Chengdu Third People's Hospital, Chengdu, Sichuan Province, 610014 |
|
|
|
|
Abstract To explore the effect of bevacizumab combined with docetaxel and gemcitabine for treating patients with recurrent platinum-resistant advanced ovarian cancer, and to study its influence of the levels of serum carbohydrate antigen 125 (CA125), human epididymal protein 4 (HE4), and high mobility group protein B1 (HMGB1), and the prognosis of the patients. Methods: A total of 62 patients with recurrent platinum-resistant advanced ovarian cancer were enrolled and were divided into observation group (31 cases)and control group (31 cases)according to random number table method from January 2019 to December 2020. The patients in the control group were treated with docetaxel and gemcitabine, while the patients in the observation group were treated with bevacizumab combined with docetaxel and gemcitabine. After 6 treatment cycles, the clinical curative effect and the occurrence of adverse reactions of the patients were compared between the two groups. The levels of serum CA125, HE4, and HMGB1 of the patients in the two groups before and after treatment were detected. The scores of Karnofsky performance status (KPS)and the survival rate within 1 year after treatment of the patients were compared between the two groups. Results: After 6 cycles of treatment, the remission rate of ovarian cancer (83.9%)and KPS score (72.13±8.78 points)of the patients in the observation group were significantly higher than those (61.3% and 63.78±7.35 points))of the patients in the control group, and the levels of serum CA125 (35.65±7.55 U/ml), HE4 (124.35±29.27 pmol/L), and HMGB1 (85.44±8.90μg/ml)of the patients in the observation group were significantly lower than those (50.22±8.95 U/ml, 175.54±26.10 pmol/L, and 100.28±12.40μg/ml)of the patients in the control group. The 1-year survival rate (74.2%)of the patients in the observation group was significantly higher than that (48.4%)of the patients in the control group (all P＜0.05). There was no significant difference in the total incidence of adverse reactions (35.5% vs.25.8%)of the patients between the two groups (P＞0.05). Conclusion: Evacizumab combined with docetaxel and gemcitabine for treating the patients with recurrent platinum-resistant advanced ovarian cancer can effectively reduce their levels of serum CA125, HE4, and HMGB1, improve their quality of life, prolong their survival time, and increase their survival rate, without the increased adverse reactions.
|
|
|
|
|
|
|
|
|
